Genfit S.A.

OTCPK:GNFT.Y Aktierapport

Börsvärde: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Framtida tillväxt

Future kriterier kontrolleras 4/6

Genfit förväntas öka intäkter och intäkter med 25.5% respektive 11% per år. EPS förväntas tillväxt med 103.2% per år. Avkastningen på eget kapital förväntas bli -2.5% om 3 år.

Viktig information

25.5%

Tillväxttakt i vinsten

103.22%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.2%
Intäkternas tillväxttakt11.0%
Framtida avkastning på eget kapital-2.51%
Bevakning av analytiker

Good

Senast uppdaterad27 Feb 2026

Senaste uppdateringarna om framtida tillväxt

Inga uppdateringar

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Prognoser för vinst- och omsättningstillväxt

OTCPK:GNFT.Y - Analytikernas framtida uppskattningar och tidigare finansiella data (EUR Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202867-29-15-153
12/31/20271078116
12/31/2026769226
12/31/202569-39-66
6/30/202545-39-7-3N/A
3/31/202558-1946N/A
12/31/20247121516N/A
9/30/20247612-14-13N/A
6/30/20248022-43-42N/A
3/31/202457-3-50-48N/A
12/31/202334-29-58-55N/A
9/30/202332-32-55-53N/A
6/30/202329-34-52-50N/A
3/31/202328-29-62-61N/A
12/31/202226-24-73-73N/A
9/30/2022601244N/A
6/30/202294488080N/A
3/31/202290589090N/A
12/31/2021856799100N/A
9/30/202146141011N/A
6/30/20216-39-79-79N/A
3/31/20217-70-88-88N/A
12/31/20209-101-97-96N/A
9/30/202024-84-73-71N/A
6/30/202039-67-49-46N/A
3/31/202039-66-49-47N/A
12/31/201939-65-50-48N/A
9/30/201923-80-62-60N/A
6/30/20198-94-73-71N/A
3/31/20198-87N/A-64N/A
12/31/20187-80N/A-56N/A
9/30/20187-75N/AN/AN/A
6/30/20187-70N/A-56N/A
3/31/20187-63N/A-53N/A
12/31/20177-56N/A-50N/A
9/30/20177-50N/AN/AN/A
6/30/20178-44N/A-40N/A
3/31/20177-39N/A-34N/A
12/31/20167-34N/A-27N/A
9/30/20166-27N/A-23N/A
6/30/20165-21N/A-18N/A
3/31/20165-19N/A-16N/A
12/31/20154-17N/A-15N/A
9/30/20155-17N/A-17N/A
6/30/20155-17N/A-19N/A
3/31/20156-17N/A-17N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: GNFT.Y förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.4% ).

Resultat vs marknad: GNFT.Y förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.

Höga tillväxtresultat: GNFT.Y förväntas bli lönsam under de kommande 3 åren.

Intäkt vs marknad: GNFT.Y s intäkter ( 11% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).

Hög tillväxtintäkter: GNFT.Y s intäkter ( 11% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: GNFT.Y förväntas bli olönsam om 3 år.

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/03/11 00:35
Aktiekurs vid dagens slut2026/03/09 00:00
Intäkter2025/06/30
Årlig intjäning2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Genfit S.A. bevakas av 14 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank